LeMaitre Vascular, Inc. (LMAT) Analysts See $0.19 EPS; Delphi Management Has Trimmed Lam Research (LRCX) Position

February 19, 2018 - By reb123z

Delphi Management Inc decreased Lam Research Corp (LRCX) stake by 9.95% reported in 2017Q3 SEC filing. Delphi Management Inc sold 1,816 shares as Lam Research Corp (LRCX)’s stock rose 32.64%. The Delphi Management Inc holds 16,435 shares with $3.04M value, down from 18,251 last quarter. Lam Research Corp now has $30.62B valuation. The stock increased 1.18% or $2.2 during the last trading session, reaching $187.91. About 4.34M shares traded or 20.33% up from the average. Lam Research Corporation (NASDAQ:LRCX) has risen 107.86% since February 19, 2017 and is uptrending. It has outperformed by 91.16% the S&P500.

Analysts expect LeMaitre Vascular, Inc. (NASDAQ:LMAT) to report $0.19 EPS on February, 20.They anticipate $0.06 EPS change or 46.15% from last quarter’s $0.13 EPS. LMAT’s profit would be $3.66M giving it 46.41 P/E if the $0.19 EPS is correct. After having $0.25 EPS previously, LeMaitre Vascular, Inc.’s analysts see -24.00% EPS growth. It closed at $35.27 lastly. It is down 101.07% since February 19, 2017 and is uptrending. It has outperformed by 84.37% the S&P500.

Investors sentiment increased to 1.02 in 2017 Q3. Its up 0.04, from 0.98 in 2017Q2. It improved, as 51 investors sold LRCX shares while 238 reduced holdings. 87 funds opened positions while 207 raised stakes. 146.35 million shares or 1.92% less from 149.22 million shares in 2017Q2 were reported. Beacon Fincl Gp reported 3,213 shares or 0.11% of all its holdings. Whittier Trust Co Of Nevada Inc reported 0.1% stake. Cornercap Inv Counsel Incorporated owns 1.08% invested in Lam Research Corporation (NASDAQ:LRCX) for 41,592 shares. Fred Alger Mgmt Incorporated holds 0.04% or 51,965 shares. Davis Selected Advisers reported 3,485 shares. Peak6 Invs Ltd Partnership has 95,769 shares for 0.09% of their portfolio. Ngam Limited Partnership has 22,751 shares. Mutual Of America Cap Ltd Com holds 0.12% or 38,227 shares in its portfolio. Gotham Asset Mgmt Ltd Liability Corporation reported 0.64% stake. Rafferty Asset Management Ltd Liability Co has invested 0.27% in Lam Research Corporation (NASDAQ:LRCX). Manufacturers Life Comm The invested 0.04% in Lam Research Corporation (NASDAQ:LRCX). Ardsley Advisory owns 0.1% invested in Lam Research Corporation (NASDAQ:LRCX) for 4,000 shares. Badgley Phelps Bell has invested 1.07% in Lam Research Corporation (NASDAQ:LRCX). Rockefeller Financial Svcs Incorporated has invested 0.01% in Lam Research Corporation (NASDAQ:LRCX). Paloma Prns Management stated it has 8,952 shares or 0.02% of all its holdings.

Among 25 analysts covering Lam Research Corporation (NASDAQ:LRCX), 24 have Buy rating, 0 Sell and 1 Hold. Therefore 96% are positive. Lam Research Corporation had 79 analyst reports since September 17, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Goldman Sachs given on Tuesday, October 25. The firm earned “Outperform” rating on Wednesday, October 21 by Cowen & Co. The company was maintained on Thursday, January 26 by Cowen & Co. Stifel Nicolaus maintained it with “Buy” rating and $116 target in Monday, November 21 report. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, January 25. The rating was maintained by UBS with “Buy” on Tuesday, June 13. The stock has “Sector Weight” rating by Pacific Crest on Wednesday, October 12. The company was maintained on Friday, July 7 by Morgan Stanley. Cowen & Co maintained the shares of LRCX in report on Thursday, December 10 with “Outperform” rating. The stock has “Buy” rating by KeyBanc Capital Markets on Sunday, November 19.

Since September 11, 2017, it had 0 insider purchases, and 11 selling transactions for $12.77 million activity. $135,000 worth of Lam Research Corporation (NASDAQ:LRCX) was sold by NEWBERRY STEPHEN G. The insider ARCHER TIMOTHY sold 15,638 shares worth $2.75 million. $5.47 million worth of Lam Research Corporation (NASDAQ:LRCX) was sold by Varadarajan Seshasayee.

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company has market cap of $679.47 million. The firm provides angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; carotid shunts to temporarily divert or shut blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and powered phlebectomy devices that enable removal of varicose veins. It has a 45.16 P/E ratio. It also offers embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude blood flow; and perfusion catheters that temporarily perfuse blood and other liquids into the vasculature.

Since August 23, 2017, it had 0 insider purchases, and 2 selling transactions for $3.18 million activity. $2.20 million worth of LeMaitre Vascular, Inc. (NASDAQ:LMAT) was sold by LeMaitre George W on Monday, August 28. Roberts David B sold $978,479 worth of stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>